A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

BACKGROUND: Gantenerumab is a fully human monoclonal antibody that binds aggregated amyloid-β (Aβ) and removes Aβ plaques by Fc receptor-mediated phagocytosis. In the SCarlet RoAD trial, we assessed the efficacy and safety of gantenerumab in prodromal Alzheimer’s disease (AD). METHODS: In this rando...

Descripción completa

Detalles Bibliográficos
Autores principales: Ostrowitzki, Susanne, Lasser, Robert A., Dorflinger, Ernest, Scheltens, Philip, Barkhof, Frederik, Nikolcheva, Tania, Ashford, Elizabeth, Retout, Sylvie, Hofmann, Carsten, Delmar, Paul, Klein, Gregory, Andjelkovic, Mirjana, Dubois, Bruno, Boada, Mercè, Blennow, Kaj, Santarelli, Luca, Fontoura, Paulo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723032/
https://www.ncbi.nlm.nih.gov/pubmed/29221491
http://dx.doi.org/10.1186/s13195-017-0318-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723032/
https://www.ncbi.nlm.nih.gov/pubmed/29221491
http://dx.doi.org/10.1186/s13195-017-0318-y

Ejemplares similares